What to Know
- Pence will take part in a roundtable discussion with school leaders and members of the Miller School of Medicine
- A news release said the school plans to use community outreach and mobile operations to recruit from a wide variety of demographics
- Participants are paid for their time and inconvenience during what is scheduled to be a three-month study
Vice President Mike Pence will make a South Florida stop Monday to mark the beginning of clinical trials for a potential coronavirus vaccine at the University of Miami.
Pence will take part in a roundtable discussion with school leaders and members of the Miller School of Medicine along with researchers on what could help in the ongoing battle with the pandemic.
As a participant of the National Institutes of Health COVID-19 Prevention Trials Network following their July 16th selection, the school plans to enroll 1,000 volunteers in South Florida in a clinical trial expected to start in the summer.
“The COVID-19 pandemic is having a tremendous impact in South Florida and across the world,” said Dr. Susanne Doblecki-Lewis, an infectious disease expert at the University of Miami who will lead the initiative. “We are testing vaccines with the goal of finding a safe and effective way to halt the spread of the virus.”
The clinical trials will test a vaccine developed by National Institutes of Health scientists and their collaborators at the biotechnology company ModernaTX Inc.
Prospective volunteers for the study will need to be at least 18 years old. A news release said the school plans to use community outreach and mobile operations to recruit from a wide variety of demographics. To register to volunteer, you can sign up by clicking here
“We are committed to engaging people who represent the range of residents impacted by COVID-19 in South Florida by gender, age, race, and ethnicity, as well as those who are particularly at-risk because of medical conditions,” said Doblecki-Lewis. “This is how we will help ensure that any vaccine that is developed will be relevant for those who could benefit most from it.”
Participants are paid for their time and inconvenience during what is scheduled to be a three-month study.
"It's not for people who are infected. It's for people who are at risk," Alcaide said.
Participants will not be intentionally infected with the disease, but rather monitored to see if the vaccine causes them to produces antibodies that counter the virus and prevent COVID-19, the disease caused by the virus.
In addition to being a hot spot, the area's racial and ethic diversity makes it an attractive backdrop for the study. Alcaide noted the disease disproportionately affects minorities in a negative way.
"We really want to reach out to all the communities that are at risk," she said, while noting that "is really everybody in Miami nowadays."
The final verdict on this vaccine and others will only come after months more testing, but Alcaide said, "it's too early to know. It’s promising and we really are hoping it will work."